Medical Supplies Stock Performance Review -- Integra LifeSciences, Antares Pharma, Becton, Dickinson and Co., and Waters
31 Aug, 2017, 06:35 ET
NEW YORK, August 31, 2017 /PRNewswire/ --
If you want a Stock Review on IART, ATRS, BDX, or WAT then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. IBISWorld reported that, over the five years to 2017, revenue for the Medical Instruments and Supplies Manufacturing industry grew modestly. As a result of healthcare reform, hospitals have increased demand for medical supplies; however, at the same time, hospital consolidation has also constrained demand for industry products. Changing demographics, healthcare reform, and product innovation will shape the industry in the coming years. Pre-market, DailyStockTracker.com evaluates Integra LifeSciences Holdings Corp. (NASDAQ: IART), Antares Pharma Inc. (NASDAQ: ATRS), Becton, Dickinson and Co. (NYSE: BDX), and Waters Corp. (NYSE: WAT). These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at:
Integra LifeSciences Holdings
Plainsboro, New Jersey headquartered Integra LifeSciences Holdings Corp.'s stock finished Wednesday's session 0.34% higher at $50.00 with a total trading volume of 479,508 shares. Over the last month and since the start of this year, the Company's shares have advanced 1.81% and 16.56%, respectively. The stock is trading above its 200-day moving average by 9.11%. Moreover, shares of the Company, which develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery, have a Relative Strength Index (RSI) of 45.71.
On August 17th, 2017, Integra LifeSciences announced that Glenn Coleman, CFO and Corporate Vice President of International, will present at the Wells Fargo Healthcare Conference on September 07th, 2017, at 10:00 a.m. ET in Boston, Massachusetts. A live audio webcast of the presentation can be accessed on the Company's Investor Relations website. Your complete research report on IART can be retrieved for free at:
Shares in Ewing, New Jersey headquartered Antares Pharma Inc. declined 2.18%, ending yesterday's session at $3.14 with a total trading volume of 1.33 million shares. The stock has gained 0.64% in the past month, 24.60% in the previous three months, and 34.76% on an YTD basis. The Company's shares are trading 0.67% above their 50-day moving average and 19.37% above their 200-day moving average. Moreover, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have an RSI of 53.18.
On August 08th, 2017, Antares Pharma reported operating and financial results for the three months ended June 30th, 2017. For Q2 2017, revenue was $13.4 million; product sales were $7.3 million; and gross profit was $7.8 million. Operating expenses were $10.5 million for the quarter and net loss was $2.8 million. At June 30th, 2017, cash, cash equivalents, and short-term investments totaled $43.4 million. A free report on ATRS is just a click away at:
Becton, Dickinson and Co.
On Wednesday, Franklin Lakes, New Jersey headquartered Becton, Dickinson and Co.'s stock saw a slight decline of 0.50%, to close the day at $197.90. A total volume of 813,853 shares was traded. The Company's shares have advanced 2.63% in the previous three months and 19.54% on an YTD basis. The stock is trading 7.68% above its 200-day moving average. Additionally, shares of the Company, which develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide, have an RSI of 47.16.
On August 03rd, 2017, Becton, Dickinson and Co. announced results for the third fiscal quarter ended June 30th, 2017. Quarterly revenues were $3.035 billion; diluted earnings per share (EPS) were $(0.75); and adjusted diluted EPS was $2.46. The Company now expects full FY17 diluted EPS to be between $5.10 and $5.15, and is raising full FY17 adjusted diluted EPS guidance to $9.42 to $9.47. Sign up for your complimentary research report on BDX at:
Shares in Milford, Massachusetts-based Waters Corp. ended the day 0.40% higher at $181.06. A total volume of 366,202 shares was traded. The stock has gained 3.03% in the last one month, 0.03% in the previous three months, and 34.73% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 0.21% and 12.29%, respectively. Furthermore, shares of Waters, which operates as an analytical instrument manufacturer in the US and internationally, have an RSI of 53.88. Register for free on DailyStockTracker.com and download the latest research report on WAT at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Share this article